Charles River Laboratories International, Inc. Announces Retirement of David P. Johst as Corporate Executive Vice President, General Counsel and Chief Administrative Officer, Effective from May 2020
Published on 08/02/2019 at 12:12
Share
On August 2, 2019, Charles River Laboratories International, Inc. announced that David P. Johst, Corporate Executive Vice President, General Counsel and Chief Administrative Officer, will retire from company in May 2020. Mr. Johst joined Charles River in 1991 as Corporate Counsel. He became Vice President, Human Resources and Administration in 1996, a Senior Vice President in 1999, and a Corporate Executive Vice President in 2005.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows:
- discovery and safety assessment services (60.5%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides;
- development and sale of research models and related services (20.5%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ;
- development of solutions used in drug manufacturing processes (19%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies.
Net sales break down by source of income between sales of services (81.6%) and sales of products (18.4%).
Net sales are distributed geographically as follows: the United States (55.3 Europe (26.6%), Canada (11.9%), Asia/Pacific (4.9%) and other (1.3%).
Charles River Laboratories International, Inc. Announces Retirement of David P. Johst as Corporate Executive Vice President, General Counsel and Chief Administrative Officer, Effective from May 2020
